Literature DB >> 17681398

PIK3CA gene amplification in Japanese non-small cell lung cancer.

Osamu Kawano, Hidefumi Sasaki, Katsuhiro Okuda, Haruhiro Yukiue, Tomoki Yokoyama, Motoki Yano, Yoshitaka Fujii.   

Abstract

We have investigated 92 non-small cell lung cancer tissues and found 11 PIK3CA amplification. PIK3CA amplification incidence was significantly higher in male, smoker and squamous cell carcinoma patients. Among 11 patients with PIK3CA amplification, two patients harbored a PIK3CA mutation. There was significant difference in survival between the patients with PIK3CA normal copy number and the patients with PIK3CA amplification.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681398     DOI: 10.1016/j.lungcan.2007.06.020

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  40 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 3.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 4.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 5.  Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.

Authors:  Corey A Carter; Giuseppe Giaccone
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

Review 6.  Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

7.  Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma.

Authors:  Marie Cumberbatch; Ximing Tang; Garry Beran; Sonia Eckersley; Xin Wang; Rebecca P A Ellston; Simon Dearden; Sabina Cosulich; Paul D Smith; Carmen Behrens; Edward S Kim; Xinying Su; Shuqiong Fan; Neil Gray; David P Blowers; Ignacio I Wistuba; Chris Womack
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

8.  The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.

Authors:  K Shoji; K Oda; S Nakagawa; S Hosokawa; G Nagae; Y Uehara; K Sone; Y Miyamoto; H Hiraike; O Hiraike-Wada; T Nei; K Kawana; H Kuramoto; H Aburatani; T Yano; Y Taketani
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

9.  Identification of driver mutations in lung cancer: first step in personalized cancer.

Authors:  David Planchard
Journal:  Target Oncol       Date:  2013-02-01       Impact factor: 4.493

Review 10.  Prognostic and predictive biomarkers in lung cancer. A review.

Authors:  Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.